Health Care [ 4/12 ] | Biotechnology [ 18/74 ]
NASDAQ | Common Stock
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.
The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial.
Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial.
The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.80 Decreased by -1.27% | -0.78 Decreased by -2.45% |
| Nov 6, 24 | -0.65 Increased by +8.45% | -0.71 Increased by +8.45% |
| Aug 9, 24 | -0.65 Increased by +1.52% | -0.79 Increased by +17.72% |
| May 9, 24 | -0.79 Decreased by -6.76% | -0.78 Decreased by -1.28% |
| Feb 28, 24 | -0.79 Increased by +10.23% | -0.66 Decreased by -19.70% |
| Nov 8, 23 | -0.71 Increased by +13.41% | -0.77 Increased by +7.79% |
| Aug 8, 23 | -0.66 Increased by +28.26% | -0.80 Increased by +17.50% |
| May 9, 23 | -0.74 Decreased by -4.23% | -0.85 Increased by +12.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.97 M Increased by +35.57% | -102.26 M Decreased by -69.18% | Decreased by -3.44 K% Decreased by -24.79% |
| Sep 30, 24 | 2.34 M Decreased by -17.10% | -80.40 M Decreased by -53.55% | Decreased by -3.44 K% Decreased by -85.24% |
| Jun 30, 24 | 2.04 M Decreased by -11.70% | -70.79 M Decreased by -50.54% | Decreased by -3.46 K% Decreased by -70.49% |
| Mar 31, 24 | 3.54 M Increased by +58.67% | -68.86 M Decreased by -45.90% | Decreased by -1.94 K% Increased by +8.04% |
| Dec 31, 23 | 2.19 M Decreased by -20.80% | -60.44 M Decreased by -26.67% | Decreased by -2.76 K% Decreased by -59.94% |
| Sep 30, 23 | 2.82 M Increased by +13.54% | -52.36 M Decreased by -23.87% | Decreased by -1.86 K% Decreased by -9.10% |
| Jun 30, 23 | 2.32 M Increased by +6.34% | -47.02 M Decreased by -2.92% | Decreased by -2.03 K% Increased by +3.21% |
| Mar 31, 23 | 2.23 M Increased by +24.40% | -47.19 M Decreased by -38.76% | Decreased by -2.11 K% Decreased by -11.54% |